MEDI0457

MEDI0457 (formerly INO-3112) is a DNA-based immunotherapy developed by Inovio Pharmaceuticals and previously licensed to MedImmune (AstraZeneca). It is designed to treat cancers caused by human papillomavirus (HPV) types 16 and 18, such as head and neck squamous cell carcinoma and cervical cancer. The therapy consists of DNA plasmids encoding the HPV 16 and 18 E6 and E7 oncoproteins, combined with a DNA plasmid encoding interleukin-12 (IL-12) as an immune activator. It is typically delivered via electroporation (using the CELLECTRA device) to induce a robust T-cell response against HPV-infected tumor cells. AstraZeneca evaluated it in combination with the PD-L1 inhibitor durvalumab before terminating the collaboration in 2021, at which point global rights returned to Inovio.

Other names

INO-3112INO3112INO 3112